Skip to main content
CAMBIUM BIO LIMITED logo

CAMBIUM BIO LIMITED — Investor Relations & Filings

Ticker · CMB ISIN · AU0000327769 ASX Professional, scientific and technical activities
Open in API
Filings indexed 504 across all filing types
Latest filing 2018-07-22 Regulatory Filings
Country AU Australia
Listing ASX CMB

About CAMBIUM BIO LIMITED

https://www.cambium.bio

Cambium Bio Limited is a clinical-stage regenerative medicine company focused on developing innovative cellular therapies to treat unmet medical needs in ophthalmology and inflammatory diseases. The company's primary focus is on its lead candidate, EluRegen, a first-in-class topical biologic designed for the treatment of corneal epithelial defects and dry eye disease. Utilizing its proprietary technology platforms, the company aims to harness the regenerative potential of biologics to provide effective treatments for chronic conditions. In addition to its ophthalmic pipeline, the company maintains assets in the field of mesenchymal stem cell therapies, including Progenza, which targets osteoarthritis and neuropathic pain. The company emphasizes a data-driven approach to clinical development, seeking to improve patient outcomes through advanced tissue engineering and cell-based solutions.

Recent filings

Filing Released Lang Actions
Response to ASX Price Query 4 pages 1.0MB
Regulatory Filings Classification · 100% confidence The document is a letter from ASX (Australian Securities Exchange) to Regeneus Ltd regarding a price query about recent trading activity in the company's securities. It requests information about any undisclosed material information that could explain the price and volume changes, compliance with listing rules, and potential need for a trading halt. The letter references Listing Rules 3.1, 3.1A, and 17.1, which relate to continuous disclosure obligations and trading halts. The document is a regulatory inquiry and request for information rather than a financial report, earnings release, or other corporate filing. It does not contain financial data, management discussion, or report content but is a compliance and disclosure-related communication. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2018-07-22 English
US Patent Office to allow key patent for Progenza 2 pages 103.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement about the United States Patent Office decision to allow a patent for the company's product Progenza. It discusses patent issuance, commercial rights, and strategic collaborations but does not contain financial data, management discussion, or regulatory certifications. The document length is 3055 characters, which is relatively short and typical for an announcement rather than a full report. There is no indication that this is a financial report, audit, earnings release, or management report. It is clearly an announcement of a patent decision, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2018-07-09 English
Update on licensing Progenza in Japan 1 page 99.6KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement from Regeneus Ltd providing an update on licensing discussions for a product called Progenza in Japan. It mentions operational expenditure funding through an R&D loan facility. The content is a brief corporate update on licensing progress and financing, without any detailed financial statements, earnings data, or regulatory certifications. The document length is short (1606 characters) and it is clearly an announcement rather than a full report or detailed financial filing. It does not fit categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Capital/Financing Update (CAP) because it includes information about a loan facility drawdown and funding for operations, which relates to financing activities.
2018-07-02 English
Grant of ASX Waiver 2 pages 165.6KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 28 June 2018 regarding the approval of an R&D loan facility and an ASX listing rule waiver. It details the terms of the loan facility, the waiver granted by ASX, and conditions related to the security over the company's assets. There are no financial statements, quarterly or annual results, or detailed financial data presented. The document is primarily an update on financing arrangements and regulatory waiver approval. This fits the category of Capital/Financing Update (CAP) as it concerns company fundraising and financing activities. The document length is about 4,824 characters, which is consistent with an announcement rather than a full report. Therefore, the appropriate classification is CAP with high confidence.
2018-06-27 English
Appendix 4C - Quarterly 6 pages 3.4MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly results for the period ended 31 March 2018' and includes detailed financial data such as cash flow statements for the quarter and year to date. It references Appendix 4C, which is a quarterly cash flow report required by ASX Listing Rule 4.7B. The content includes actual financial figures, cash flow from operating, investing, and financing activities, and commentary on funding sources and cash position. This matches the characteristics of an Interim / Quarterly Report (IR) as it provides comprehensive financial data for a period shorter than a full fiscal year. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). Q3 2018
2018-04-25 English
Appendix 3Y Change of Director's Interest Notice 2 pages 220.2KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in relevant interests in securities, including the number of shares acquired and disposed, nature of the change (on-market trade), and other related information. The document is a formal notification of a director's personal share transactions. It does not contain financial statements, earnings data, or management discussion. It fits the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 3330 characters, consistent with a notice rather than a full report. Therefore, the correct classification is DIRS.
2018-04-19 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.